FCM
ALNY icon

Farallon Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Farallon Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-100,000
Closed -$39.8M – 174
2025
Q4 		$39.8M Hold
100,000
– – 0.18% 59
2025
Q3 		$45.6M Buy
+100,000
New +$40.7M 0.19% 59

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Farallon Capital Management's ALNY Position: Q2 2024 in Review

Farallon Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2024, closing a stake of 2,000 shares — an estimated $299K sold.

Farallon Capital Management first reported a position in ALNY in Q2 2017 and held it in 26 quarters. The position peaked at $202M in Q4 2021. 521 funds tracked by Wall St. Rank hold ALNY as of Q2 2024.

  • Farallon Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Farallon Capital Management sold 2,000 Alnylam Pharmaceuticals shares in Q2 2024, an estimated $299K.
  • Farallon Capital Management first reported a position in Alnylam Pharmaceuticals in Q2 2017 and held it in 26 quarters.
  • Farallon Capital Management's Alnylam Pharmaceuticals position peaked at $202M in Q4 2021.
  • 521 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2024.

Based on Farallon Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.